<div id="readability-page-1"><div> NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. (&#34;GeneDx&#34; or the &#34;Company&#34;) (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. <img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="75" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg"/> The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 4, 2026, GeneDx reported its first quarter 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed total revenue of $102.3 million, exome and genome revenue of $90.6 million, and exome and genome test volume growth of 34% year-over-year. Despite this strong volume growth, GeneDx disclosed that exome and genome revenue increased only 27% year-over-year. The Company also reduced its full-year 2026 revenue guidance to $475 million to $490 million, compared to prior guidance of $540 million to $555 million, and reduced its expected growth in exome and genome revenue to at least 20%, compared to prior guidance of 33% to 35%. During the associated earnings call, GeneDx further disclosed that total revenue was approximately $12 million below expectations, including approximately $5.5 million due to a lower-than-expected blended average reimbursement rate for exome and genome testing, and approximately $6.5 million due to softer-than-expected performance from non-core business lines. On this news, GeneDx's stock price fell $33.42 per share, or 49.20%, to close at $34.51 per share on May 5, 2026.Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0wNyZzbj1EQzU0NjI5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0wNyZzbj1EQzU0NjI5"/> View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-genedx-holdings-corp---wgs-302766315.htmlSOURCE Pomerantz LLP</div></div>

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

Pomerantz 律师事务所正在代表 GeneDx Holdings Corp.（纳斯达克：WGS）的投资者调查有关潜在证券欺诈或非法商业行为的索赔。GeneDx 最近公布了 2026 年第一季度财务业绩，显示总收入为 1.023 亿美元，但将全年收入指引下调至 4.75 亿至 4.90 亿美元，低于之前的 5.40 亿至 5.55 亿美元。此消息发布后，GeneDx 的股价暴跌 49.20%，降至每股 34.51 美元。鼓励投资者联系 Pomerantz 以获取有关加入集体诉讼的更多信息

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

MorningStar

GeneDx

医疗业 ETF - SPDR

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

基因免疫&健康关怀 ETF - iShares

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

GeneDx - CW27

投资者警报：Pomerantz 律师事务所代表 GeneDx Holdings Corp.的投资者进行索赔调查 - WGS